Home » Stocks » Zogenix

Zogenix, Inc. (ZGNX)

Stock Price: $24.26 USD 0.57 (2.41%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 1.34B
Revenue (ttm) 4.90M
Net Income (ttm) -425.66M
Shares Out 55.34M
EPS (ttm) -9.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $24.26
Previous Close $23.69
Change ($) 0.57
Change (%) 2.41%
Day's Open 23.82
Day's Range 23.80 - 24.67
Day's Volume 1,487,901
52-Week Range 16.65 - 57.22

More Stats

Market Cap 1.34B
Enterprise Value 964.97M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 55.34M
Float 43.58M
EPS (basic) -9.45
EPS (diluted) -9.20
FCF / Share -2.79
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 7.33M
Short Ratio 3.97
Short % of Float 12.44%
Beta 1.62
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 274.16
PB Ratio 2.92
Revenue 4.90M
Operating Income -461.55M
Net Income -425.66M
Free Cash Flow -154.55M
Net Cash 377.59M
Net Cash / Share 6.82
Gross Margin -2,286.93%
Operating Margin -9,425.08%
Profit Margin -8,758.50%
FCF Margin -3,155.95%
ROA -19.12%
ROE -86.57%
ROIC -241.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (12)

Buy 10
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$48.17*
(98.56% upside)
Low
26.0
Current: $24.26
High
69.0
Target: 48.17
*Average 12-month price target from 12 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue3.65-9.8228.8527.1828.9533.0144.3337.5823.44
Revenue Growth---65.96%6.14%-6.1%-12.31%-25.52%17.96%60.29%-
Gross Profit3.65--0.916.684.839.3411.7724.8318.2810.60
Operating Income-424-140-95.84-70.89-49.73-38.62-44.94-47.43-76.42-70.16
Net Income-420-124-127-69.7126.148.59-80.86-47.39-83.90-73.56
Shares Outstanding43.0837.8827.3024.7921.4517.8313.5710.075.340.52
Earnings Per Share-9.74-3.27-4.65-2.811.220.48-5.96-4.72-15.68-141.04
EPS Growth----154.17%-----
Operating Cash Flow-112-112-75.87-72.88-64.60-80.82-44.92-52.20-80.47-71.95
Capital Expenditures-9.49-1.02-0.08-0.10-0.31-0.12-0.81-0.29-0.62-3.44
Free Cash Flow-121-113-75.95-72.98-64.91-80.94-45.73-52.50-81.09-75.39
Cash & Equivalents25151429491.5516550.7172.0241.2356.5349.17
Total Debt12.07--22.0922.2223.1528.8028.4856.9126.90
Net Cash / Debt23951429469.4614327.5543.2212.75-0.3822.27
Assets41464841823230620311380.6910194.27
Liabilities16912611611112314894.0866.2191.3365.53
Book Value24552330212118355.2818.4314.479.3128.73
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Zogenix, Inc.
Country United States
Employees 141
CEO Stephen James Farr

Stock Information

Ticker Symbol ZGNX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ZGNX
IPO Date November 23, 2010

Description

Zogenix, Inc., a pharmaceutical company, develops and commercializes transformative therapies to enhance the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome (LGS); and which is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It also developing MT1621, an investigational deoxynucleoside substrate enhancement therapy for the treatment of inherited mitochondrial DNA depletion disorder thymidine kinase 2 deficiency (TK2d). The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California.